期刊文献+

非酒精性脂肪性肝病大鼠肝X受体α和固醇调节元件结合蛋白-1c的表达及意义 被引量:10

Significance and effect of liver X receptor α and sterol regulatory element binding protein-1c in non-alcoholic fatty liver disease in rats
下载PDF
导出
摘要 目的观察肝X受体α(LXRα)和固醇调节元件结合蛋白-1c(SREBP-1c)在大鼠非酒精性脂肪性肝病(NAFLD)中的表达变化,以探讨二者在NAFLD形成过程中的作用及可能机制。方法建立高脂饮食诱导NAFLD大鼠模型后,采用逆转录聚合酶链反应(RT-RCR)和Western blot法动态观察NAFLD大鼠肝组织中LXRα和SREBP-1c表达变化。结果与对照组相比,NAFLD组大鼠肝组织中LXRα和SREBP-1c基因和蛋白表达,从第2周开始增加,12周时升高最显著(P<0.01),与脂肪肝进展程度一致。结论LXRα和SREBP-1c的表达变化与NAFLD的形成密切相关。 Objective To explore the significance and effect of the expression changes of liver X receptor α (LXRα) and sterol regulatory element binding protein-1c (SREBP-1c) in non-alcoholic fatty liver disease (NAFLD) in rats. Methods The rat model of nonalcoholic fatty liver disease was established with fatty diet. The mRNA and protein expression of LXRα and SREBP-1c in liver tissue were detected by reverse transcription and polymerase chain reaction (RT-PCR) and Western blot. Results Compared with Group C, in Group F, the mRNA and protein expression of LXRα and SREBP-1c in 2 week were significantly increased, and their peak was reached in 12 week (P〈0.01). There was significantly positive correlation between the expression of them and the degree of NAFLD. Conclusion The expression changes of LXRα and SREBP-1c are closely related to the development of non-alcoholic fatty liver disease.
出处 《重庆医学》 CAS CSCD 2007年第8期689-691,共3页 Chongqing medicine
关键词 非酒精性脂肪性肝病 肝X受体Α 固醇调节元件结合蛋白-1C 脂代谢紊乱 non-alcoholic fatty liver disease liver X receptor α sterol regulatory element binding protein lipid metabolism disorder
  • 相关文献

参考文献10

  • 1Houck KA,Borchert KM,Hepler CD,et al.T0901317 is a dual LXR/FXR agonist[J].Mol Genet Metab,2004,83(1-2):184
  • 2Jump BD,Botolin D,Wang Y,et al.Fatty acid regulation of hepatic gene transcription[J].J Nutr,2005,135(11):2503
  • 3Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量:1510
  • 4Rant DB,Ronald ME.PPARs and LXRs:atherosclerosis goes nuclear[J].Trends Endocrinol Metab,2004,15(4):158
  • 5Edwards PA,Tabor D,Kast HR,et al.Regulation of gene expression by SREBP and SCAP[J].Biochim Biophys,2000,1529(1-3):103
  • 6Sewter C,Berger D.Human obesity and type 2 diabetes are associated with alterations in SREBP1 isoform expression that are reptoduced ex vivo by tumor necrosis factor-alpha[J].Diabetes,2002,51(4):1035
  • 7艾正琳,陈东风.SREBP-1c在大鼠非酒精性脂肪性肝病中的表达及意义[J].第三军医大学学报,2006,28(10):1063-1065. 被引量:35
  • 8Bobard A,Hainault I,Ferre P,et al.Differantial regulation of SREBP-1c transcriptional activity by insulin and LXR during liver development[J].J Biol Chem,2005,280(1):199
  • 9Larter CZ,Farrell GC.Insulin resistance,adiponectin,cytokinase in NASH:which is the best target of treat[J].J Hepatology,2006,44(2):253
  • 10Abildayeva K,Jansen PJ,Hirsch-Reinshagen V.24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux[J].J Biol Chem,2006,281(18):12799

二级参考文献24

  • 1冯爱娟,王军,陈东风.FATP4在大鼠非酒精性脂肪肝中的作用[J].第三军医大学学报,2004,26(19):1726-1728. 被引量:7
  • 2胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 3Schwimmer JB,Behling C,Newbury R,et al.Histopathology of pediatric nonalcoholic fatty liver disease.Hepatology,2005,42:641-649.
  • 4Neuschwander Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference.Hepatology,2003,37:1202-1219.
  • 5Angulo P.Nonalcoholic fatty liver disease.N Engl J Med,2002,346:1221-1231.
  • 6Ghali P,Lindor KD.Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.Semin Liver Dis,2004,24:389-397.
  • 7Harrison SA,Torgerson S,Hayashi P,et al.Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.Am J Gastroenterol,2003,98:2485-2490.
  • 8Angulo P.Use of ursodeoxycholic acid in patients with liver disease.Curr Gastroenterol Rep,2002,4:37-44.
  • 9Agrawal S,Bonkovsky HL.Management of nonalcoholic steatohepatitis:an analytic review.J Clin Gastroenterol,2002,35:253-261.
  • 10Comar KM,Sterling RK.Drug therapy for non-alcoholic fatty liver disease.Aliment Pharmacal Ther,2006,23:207-215.

共引文献1542

同被引文献107

引证文献10

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部